Cargando…

Transcription Factors as Novel Therapeutic Targets and Drivers of Prostate Cancer Progression

Prostate cancer is the second most diagnosed cancer among men worldwide. Androgen deprivation therapy, the most common targeted therapeutic option, is circumvented as prostate cancer progresses from androgen dependent to castrate-resistant disease. Whilst the nuclear receptor transcription factor, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Kangzhe, Tan, Keely, Naylor, Matthew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082354/ https://www.ncbi.nlm.nih.gov/pubmed/35547880 http://dx.doi.org/10.3389/fonc.2022.854151

Ejemplares similares

Tumour Microenvironment-Immune Cell Interactions Influencing Breast Cancer Heterogeneity and Disease Progression
por: Tan, Keely, et al.
Publicado: (2022)

The Influence of Modifiable Factors on Breast and Prostate Cancer Risk and Disease Progression
por: Tan, Keely, et al.
Publicado: (2022)

Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells
por: Civenni, Gianluca, et al.
Publicado: (2019)

Editorial: Transcription Factors Drivers of Malignancy, Progression and Poor Outcomes in Breast Cancer
por: Parisi, Eva, et al.
Publicado: (2022)

Therapeutically Targeting Cancers That Overexpress FOXC1: A Transcriptional Driver of Cell Plasticity, Partial EMT, and Cancer Metastasis
por: Ray, Tania, et al.
Publicado: (2021)

Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
por: Marsh, Deborah J., et al.
Publicado: (2014)

Identification of the novel therapeutic targets and biomarkers associated of prostate cancer with cancer-associated fibroblasts (CAFs)
por: Zhai, Xinyu, et al.
Publicado: (2023)

Editorial: Identification of therapeutic targets and novel biomarkers in prostate cancer volume II
por: Sharad, Shashwat, et al.
Publicado: (2023)

Driver Gene Alterations in Malignant Progression of Gastric Cancer
por: Dong, Yuanqiang, et al.
Publicado: (2022)

Monoamine oxidase A: An emerging therapeutic target in prostate cancer
por: Chen, Chia-Hui, et al.
Publicado: (2023)

Editorial: Cancer-Associated Defects in the DNA Damage Response: Drivers for Malignant Transformation and Potential Therapeutic Targets
por: van Vugt, Marcel A. T. M., et al.
Publicado: (2015)

Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma
por: Dreher, Rachel D., et al.
Publicado: (2023)

State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer
por: Ramesh, Saravanan, et al.
Publicado: (2023)

Recent Progress in Understanding the Action of Natural Compounds at Novel Therapeutic Drug Targets for the Treatment of Liver Cancer
por: Zheng, Yannan, et al.
Publicado: (2022)

Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer
por: Adorno Febles, Victor R., et al.
Publicado: (2020)

Strategies to target the cancer driver MYC in tumor cells
por: Weber, Leonie I., et al.
Publicado: (2023)

FMO family may serve as novel marker and potential therapeutic target for the peritoneal metastasis in gastric cancer
por: Gong, Xumeng, et al.
Publicado: (2023)

Transcription factor E2F8 is a therapeutic target in the basal-like subtype of breast cancer
por: Zheng, Jing, et al.
Publicado: (2023)

Dynamic Interactions of Transcription Factors and Enhancer Reprogramming in Cancer Progression
por: Zboril, Emily, et al.
Publicado: (2021)

Recent Progress on Therapeutic Vaccines for Breast Cancer
por: Zhang, Lianru, et al.
Publicado: (2022)

Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications
por: Ryan, Matthew J., et al.
Publicado: (2019)

Risk Factors and Therapeutic Targets in Pancreatic Cancer
por: Wörmann, Sonja Maria, et al.
Publicado: (2013)

Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer
por: Daoud, Alia, et al.
Publicado: (2017)

Putative Breast Cancer Driver Mutations in TBX3 Cause Impaired Transcriptional Repression
por: Fischer, Kathrin, et al.
Publicado: (2015)

Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer
por: Shen, Yanting, et al.
Publicado: (2021)

Metal-Regulatory Transcription Factor-1 Targeted by miR-148a-3p Is Implicated in Human Hepatocellular Carcinoma Progression
por: Lyu, Zhuozhen, et al.
Publicado: (2021)

Progress in Gene Therapy for Prostate Cancer
por: Ahmed, Kamran A., et al.
Publicado: (2012)

Glycosylation Changes in Prostate Cancer Progression
por: Butler, William, et al.
Publicado: (2021)

Progression in immunotherapy for advanced prostate cancer
por: Liang, Hao, et al.
Publicado: (2023)

BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target
por: Bezrookove, Vladimir, et al.
Publicado: (2022)

Forkhead Box Transcription Factors in Cancer Initiation, Progression and Chemotherapeutic Drug Response
por: Lam, Eric W.-F., et al.
Publicado: (2014)

Editorial: Interplay between epigenetic modifiers and transcription factors in driving cancer progression
por: Yang, Yongyong, et al.
Publicado: (2023)

Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications
por: Di Zazzo, Erika, et al.
Publicado: (2018)

Prostate Cancer Progression: as a Matter of Fats
por: Scaglia, Natalia, et al.
Publicado: (2021)

The Roles of Embryonic Transcription Factor BRACHYURY in Tumorigenesis and Progression
por: Chen, Ming, et al.
Publicado: (2020)

Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer
por: Ripoll, Giselle V., et al.
Publicado: (2020)

Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets
por: He, Jiangnan, et al.
Publicado: (2021)

TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer
por: Saldías, María Paz, et al.
Publicado: (2021)

Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?
por: Fidelito, Gio, et al.
Publicado: (2022)

Mitochondrial Dysfunction: A Novel Potential Driver of Epithelial-to-Mesenchymal Transition in Cancer
por: Guerra, Flora, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vule7582p87a5n8qfqd6b56h58